A Real Life Study on Treatment of Egyptian Patients with HCV Genotype IV with Simeprevir and Sofosbuvir

ISSN Print: 1949-4998
ISSN Online: 1949-5005
www.scirp.net/journal/health
E-mail: [email protected]

Citations

"A Real Life Study on Treatment of Egyptian Patients with HCV Genotype IV with Simeprevir and Sofosbuvir"
written by A. Hanno, D. Elwazzan, M. Ibrahim, R. Hafez,
published by Health, Vol.8 No.9, 2016

has been cited by the following article(s):

[1]	Mathematical Processing of Absorption as Green Smart Spectrophotometric Methods for Concurrent Assay of Hepatitis C Antiviral Drugs, Sofosbuvir and …
	2022

[2]	Mathematical Processing of Absorption as Green Smart Spectrophotometric Methods for Concurrent Assay of Hepatitis C Antiviral Drugs, Sofosbuvir and Simeprevir …
	2022

[3]	The outcome of re-treatment of relapsed hepatitis C virus infection in a resource-limited setting
	2021

[4]	Real Life Egyptian Experience of Daclatasvir plus Sofosbuvir with Ribavirin in Naive Difficult to Treat HCV Patients
	2020

[5]	Sofosbuvir in combination with ribavirin or simeprevir: real-life study of patients with hepatitis C genotype 4
	2019

[6]	Safety and efficacy of sofosbuvir and simeprevir versus sofosbuvir and daclatasvir in treatment of naïve Egyptian patients with chronic hepatitis C virus infection
	2018

[7]	Safety and efficacy of combination therapy (Simeprevir/Sofosbuvir) in the treatment of chronic HCV genotype IV patients
	2018

[8]	Safety and Efficacy of Sofosbuvir and Simeprevir Versus Sofosbuvir and Daclatasvir in Treatment of Naïve Egyptian Patients with Chronic Hepatitis C Virus …
	2018

[9]	Determinants of Infection Outcome in HCV-Genotype 4
	2017

[10]	Management of Hepatitis C Virus—Genotypes 4, 5, and 6 Using Direct Antiviral Agents: Review of Current Status
	Current Treatment Options in Infectious Diseases, 2016

[1]	Mathematical processing of absorption as green smart spectrophotometric methods for concurrent assay of hepatitis C antiviral drugs, Sofosbuvir and Simeprevir: application to combined pharmaceutical dosage forms and evaluation of the method greenness BMC Chemistry, 2023 DOI:10.1186/s13065-023-00984-5

[2]	The outcome of re-treatment of relapsed hepatitis C virus infection in a resource-limited setting VirusDisease, 2021 DOI:10.1007/s13337-021-00712-4

[3]	Real Life Egyptian Experience of Daclatasvir Plus Sofosbuvir with Ribavirin in Naïve Difficult to Treat HCV Patients Infectious Disorders - Drug Targets , 2020 DOI:10.2174/1871526518666180716141806

[4]	Determinants of Infection Outcome in HCV-Genotype 4 Viral Immunology, 2017 DOI:10.1089/vim.2017.0071

[5]	Management of Hepatitis C Virus—Genotypes 4, 5, and 6 Using Direct Antiviral Agents: Review of Current Status Current Treatment Options in Infectious Diseases, 2016 DOI:10.1007/s40506-016-0094-4